{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:51:52Z","timestamp":1784303512899,"version":"3.55.0"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The management of multidrug-resistant tuberculosis (MDR TB) is notably complex among patients with human immunodeficiency virus (HIV). TB treatment recommendations typically include very little information specific to HIV and MDR TB, which often is derived from clinical trials conducted in low-resource settings. Mortality rates among patients with HIV and MDR TB remain high. We reviewed the published literature and recommendations to synthesize possible patient management approaches demonstrated to improve treatment outcomes in high-resourced countries for patients with MDR TB and HIV. Approaches to diagnostic testing, impact and timing of antiretroviral therapy on mortality, anti\u2013MDR TB and antiretroviral drug interactions, and the potential role for short-course MDR TB therapy are examined. The combination of antiretroviral therapy with expanded TB drug therapy, along with the management of immune reconstitution inflammatory syndrome, other potential HIV-associated opportunistic diseases, and drug toxicities, necessitate an integrated multidisciplinary patient care approach using public health case management and provider expertise in drug-resistant TB and HIV management.<\/jats:p>","DOI":"10.1513\/annalsats.201902-185cme","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T17:24:21Z","timestamp":1564593861000},"page":"16-23","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":18,"title":["Multidrug-Resistant Tuberculosis in Patients with Human Immunodeficiency Virus. Management Considerations within High-resourced Settings"],"prefix":"10.1093","volume":"17","author":[{"given":"John W.","family":"Wilson","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Nilsen","sequence":"additional","affiliation":[{"name":"Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, Queens, New York, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Marks","sequence":"additional","affiliation":[{"name":"Data Management, Statistics, and Evaluation Branch, Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,1]]},"reference":[{"key":"2026012203410083900_bib1","first-page":"1509","article-title":"Mortality among patients with tuberculosis and associations with HIV status\u2014United States, 1993\u20132008","volume":"59","author":"Shah","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026012203410083900_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2105\/AJPH.2009.177725","article-title":"Tuberculosis rates among HIV-infected persons in New York City, 2001\u20132005","volume":"100","author":"Trieu","year":"2010","journal-title":"Am J Public Health"},{"key":"2026012203410083900_bib3","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/00002030-200006160-00020","article-title":"Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda","volume":"14","author":"Whalen","year":"2000","journal-title":"AIDS"},{"key":"2026012203410083900_bib4","first-page":"225","article-title":"Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area","volume":"5","author":"Badri","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012203410083900_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/oxfordjournals.aje.a009105","article-title":"Progression of human immunodeficiency virus infection in patients with tuberculosis disease: a cohort study in Bordeaux, France, 1988\u20131994. The Groupe d\u2019Epid\u00e9miologie Clinique du Sida en Aquitaine (GECSA)","volume":"145","author":"Leroy","year":"1997","journal-title":"Am J Epidemiol"},{"key":"2026012203410083900_bib6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1097\/QAD.0b013e32830e010c","article-title":"Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence","volume":"22","author":"L\u00f3pez-Gatell","year":"2008","journal-title":"AIDS"},{"key":"2026012203410083900_bib7","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid","volume":"353","author":"Vernon","year":"1999","journal-title":"Lancet"},{"key":"2026012203410083900_bib8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1164\/ajrccm.153.2.8564140","article-title":"Independent origin of mono-rifampin\u2013resistant Mycobacterium tuberculosis in patients with AIDS","volume":"153","author":"Lutfey","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203410083900_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1086\/430377","article-title":"Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997\u20132000","volume":"41","author":"Li","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2026012203410083900_bib10","doi-asserted-by":"crossref","first-page":"e82235","DOI":"10.1371\/journal.pone.0082235","article-title":"Association between HIV\/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis","volume":"9","author":"Mesfin","year":"2014","journal-title":"PLoS One"},{"key":"2026012203410083900_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/infdis\/jis631","article-title":"Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa","volume":"207","author":"Gandhi","year":"2013","journal-title":"J Infect Dis"},{"key":"2026012203410083900_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1604544","article-title":"Transmission of extensively drug-resistant tuberculosis in South Africa","volume":"376","author":"Shah","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012203410083900_bib13","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S1473-3099(18)30537-1","article-title":"Transmission of drug-resistant tuberculosis in HIV-endemic settings","volume":"19","author":"Khan","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026012203410083900_bib14","author":"Centers for Disease Control and Prevention"},{"key":"2026012203410083900_bib15","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1038\/s41598-018-23344-z","article-title":"Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis","volume":"8","author":"Samuels","year":"2018","journal-title":"Sci Rep"},{"key":"2026012203410083900_bib16","doi-asserted-by":"crossref","first-page":"e0193491","DOI":"10.1371\/journal.pone.0193491","article-title":"Outcomes of HIV-infected versus HIV\u2013non-infected patients treated for drug-resistance tuberculosis: multicenter cohort study","volume":"13","author":"Bastard","year":"2018","journal-title":"PLoS One"},{"key":"2026012203410083900_bib17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5588\/ijtld.11.0153","article-title":"Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting","volume":"16","author":"Gandhi","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012203410083900_bib18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3201\/eid2005.131037","article-title":"Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005\u20132007","volume":"20","author":"Marks","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2026012203410083900_bib19","volume-title":"Rapid communication: key changes to treatment of multidrug-and rifampicin-resistant tuberculosis (MDR\/RR-TB)","author":"World Health Organization","year":"2018"},{"key":"2026012203410083900_bib20","article-title":"WHO treatment guidelines for drug-resistant tuberculosis 2016 update","author":"World Health Organization","year":"2016"},{"key":"2026012203410083900_bib21","author":"U.S. Department of Health and Human Services Services"},{"key":"2026012203410083900_bib22","author":"Curry International Tuberculosis Center and California Department of Public Health"},{"key":"2026012203410083900_bib23","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"2026012203410083900_bib24","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Taylor","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"2026012203410083900_bib25","first-page":"1","article-title":"Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings","volume":"55","author":"Branson","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"2026012203410083900_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/09031936.00203811","volume-title":"European union standards for tuberculosis care","author":"Migliori","year":"2012"},{"key":"2026012203410083900_bib27","volume-title":"WHO policy on collaborative TB\/HIV activities: guidelines for national programmes and other stakeholders 2012","author":"World Health Organization","year":"2014"},{"key":"2026012203410083900_bib28","article-title":"Implementing the end TB strategy: the essentials","author":"World Health Organization","year":"2015"},{"key":"2026012203410083900_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026012203410083900_bib30","first-page":"7","article-title":"Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis","volume":"58","author":"Centers for Disease Control and Prevention (CDC)","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026012203410083900_bib31","volume-title":"The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: policy guidance","author":"World Health Organization","year":"2015"},{"key":"2026012203410083900_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2334-12-103","article-title":"Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review","volume":"12","author":"Lawn","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2026012203410083900_bib33","doi-asserted-by":"crossref","first-page":"e1001760","DOI":"10.1371\/journal.pmed.1001760","article-title":"Impact of Xpert MTB\/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial","volume":"11","author":"Cox","year":"2014","journal-title":"PLoS Med"},{"key":"2026012203410083900_bib34","doi-asserted-by":"crossref","first-page":"e0116721","DOI":"10.1371\/journal.pone.0116721","article-title":"Catching the missing million: experiences in enhancing TB & DR-TB detection by providing upfront Xpert MTB\/RIF testing for people living with HIV in India","volume":"10","author":"Raizada","year":"2015","journal-title":"PLoS One"},{"key":"2026012203410083900_bib35","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa0907847","article-title":"Rapid molecular detection of tuberculosis and rifampin resistance","volume":"363","author":"Boehme","year":"2010","journal-title":"N Engl J Med"},{"key":"2026012203410083900_bib36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1473-3099(17)30691-6","article-title":"Xpert MTB\/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study","volume":"18","author":"Dorman","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026012203410083900_bib37","doi-asserted-by":"crossref","first-page":"e01717","DOI":"10.1128\/JCM.01717-18","article-title":"Added value of Xpert MTB\/RIF Ultra for diagnosis of pulmonary tuberculosis in a low-prevalence setting","volume":"57","author":"Opota","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2026012203410083900_bib38","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1128\/JCM.01958-12","article-title":"The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB\/RIF assay","volume":"50","author":"Barnard","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2026012203410083900_bib39","author":"Centers for Disease Control and Prevention"},{"key":"2026012203410083900_bib40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/cid\/ciy937","article-title":"Evaluation of the impact of a sequencing assay for detection of drug resistance on the clinical management of tuberculosis","volume":"69","author":"Lowenthal","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026012203410083900_bib41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1128\/JCM.01821-13","article-title":"Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens","volume":"52","author":"Lin","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2026012203410083900_bib42","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1128\/JCM.00298-17","article-title":"Comprehensive whole-genome sequencing and reporting of drug resistance profiles on clinical cases of Mycobacterium tuberculosis in New York State","volume":"55","author":"Shea","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2026012203410083900_bib43","doi-asserted-by":"crossref","first-page":"e47370","DOI":"10.1371\/journal.pone.0047370","article-title":"Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review","volume":"7","author":"Arentz","year":"2012","journal-title":"PLoS One"},{"key":"2026012203410083900_bib44","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(13)62675-6","article-title":"Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study","volume":"383","author":"Pietersen","year":"2014","journal-title":"Lancet"},{"key":"2026012203410083900_bib45","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/S0140-6736(10)60492-8","article-title":"Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study","volume":"375","author":"Dheda","year":"2010","journal-title":"Lancet"},{"key":"2026012203410083900_bib46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/QAI.0b013e31821190a3","article-title":"Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients","volume":"57","author":"Kvasnovsky","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026012203410083900_bib47","doi-asserted-by":"crossref","first-page":"e46943","DOI":"10.1371\/journal.pone.0046943","article-title":"Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho","volume":"7","author":"Satti","year":"2012","journal-title":"PLoS One"},{"key":"2026012203410083900_bib48","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012203410083900_bib49","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"key":"2026012203410083900_bib50","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012203410083900_bib51","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012203410083900_bib52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5588\/ijtld.13.0627","article-title":"Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial","volume":"18","author":"Padayatchi","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012203410083900_bib53","volume-title":"Treatment of tuberculosis: guidelines","author":"World Health Organization","year":"2010"},{"key":"2026012203410083900_bib54","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","journal-title":"Clin Infect Dis"},{"key":"2026012203410083900_bib55","doi-asserted-by":"crossref","first-page":"e15841","DOI":"10.1371\/journal.pone.0015841","article-title":"Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa","volume":"6","author":"Brust","year":"2011","journal-title":"PLoS One"},{"key":"2026012203410083900_bib56","doi-asserted-by":"crossref","first-page":"e108035","DOI":"10.1371\/journal.pone.0108035","article-title":"Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment","volume":"9","author":"Tierney","year":"2014","journal-title":"PLoS One"},{"key":"2026012203410083900_bib57","doi-asserted-by":"crossref","first-page":"e0198080","DOI":"10.1371\/journal.pone.0198080","article-title":"Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia","volume":"13","author":"Shibabaw","year":"2018","journal-title":"PLoS One"},{"key":"2026012203410083900_bib58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S2213-2600(15)00036-3","article-title":"Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies","volume":"3","author":"Kurbatova","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026012203410083900_bib59","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","article-title":"Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome","volume":"24","author":"Meintjes","year":"2010","journal-title":"AIDS"},{"key":"2026012203410083900_bib60","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1800762","article-title":"Prednisone for the prevention of paradoxical tuberculosis-associated IRIS","volume":"379","author":"Meintjes","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012203410083900_bib61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/cid\/ciw763","article-title":"The long-term mortality of patients with tuberculosis meningitis in New York City: a cohort study","volume":"64","author":"Vinnard","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026012203410083900_bib62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/430616","article-title":"Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis","volume":"192","author":"Thwaites","year":"2005","journal-title":"J Infect Dis"},{"key":"2026012203410083900_bib63","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","article-title":"Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)\u2014associated tuberculous meningitis","volume":"52","author":"T\u00f6r\u00f6k","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026012203410083900_bib64","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/eri.13.39","article-title":"Drug-resistant tuberculous meningitis","volume":"11","author":"Garg","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026012203410083900_bib65","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"2026012203410083900_bib66","author":"U.S. Centers for Disease Control and Prevention"},{"key":"2026012203410083900_bib67","doi-asserted-by":"crossref","first-page":"e0133452","DOI":"10.1371\/journal.pone.0133452","article-title":"Factors associated with the development of drug resistance mutations in HIV-1 infected children failing protease inhibitor-based antiretroviral therapy in South Africa","volume":"10","author":"Rossouw","year":"2015","journal-title":"PLoS One"},{"key":"2026012203410083900_bib68","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archinte.166.12.1280","article-title":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors","volume":"166","author":"Ehret","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026012203410083900_bib69","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejphar.2010.10.010","article-title":"Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking","volume":"650","author":"Han","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"2026012203410083900_bib70","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMoa022147","article-title":"Risk stratification in the long-QT syndrome","volume":"348","author":"Priori","year":"2003","journal-title":"N Engl J Med"},{"key":"2026012203410083900_bib71","doi-asserted-by":"crossref","first-page":"ofz167","DOI":"10.1093\/ofid\/ofz167","article-title":"Tuberculosis in the United States: medical consultation services provided by 5 tuberculosis regional training and medical consultation centers, 2013-2017","volume":"6","author":"Goswami","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026012203410083900_bib72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1183\/09031936.00196712","article-title":"Supporting TB clinicians managing difficult cases: the ERS\/WHO Consilium","volume":"41","author":"Blasi","year":"2013","journal-title":"Eur Respir J"},{"key":"2026012203410083900_bib73","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203410083900_bib74","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20189-month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012203410083900_bib75","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5588\/ijtld.14.0535","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"Kuaban","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012203410083900_bib76","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","article-title":"High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses","volume":"18","author":"Piubello","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012203410083900_bib77","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5588\/ijtld.17.0498","article-title":"Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries","volume":"22","author":"Tr\u00e9bucq","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012203410083900_bib78","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203410083900_bib79","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/QAI.0000000000001018","article-title":"Timing of antiretroviral treatment, immunovirologic status and TB risk: Implications for test and treat","volume":"72","author":"Pettit","year":"2016","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/17\/1\/16\/66349462\/annalsats_17_1_16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/17\/1\/16\/66349462\/annalsats_17_1_16.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:45:42Z","timestamp":1769071542000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/17\/1\/16\/8419357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,1]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201902-185cme","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2020,1,1]]},"assertion":[{"value":"2019-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}